tiprankstipranks
Trending News
More News >

Sino Biopharmaceutical’s Anqixin® Approved for Marketing in China

Story Highlights
Sino Biopharmaceutical’s Anqixin® Approved for Marketing in China

Don’t Miss TipRanks’ Half-Year Sale

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical Limited has announced the approval of its self-developed drug, Anqixin®, a recombinant human coagulation factor VIIa for injection, by the National Medical Products Administration of China. This approval marks the first domestically produced product of its kind in China, offering an economical and high-quality treatment option for hemophilia patients with inhibitors. The drug’s efficacy and safety were confirmed through a Phase III clinical trial, demonstrating a hemostatic efficacy rate of 88.93%. The company has developed proprietary processes for production, ensuring quality consistency across batches, and holds patents for its innovative methods. This development positions Sino Biopharmaceutical as a significant player in the hemophilia treatment market, potentially benefiting a broader population of patients.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company involved in the biopharmaceutical industry, focusing on the development and marketing of innovative drugs. The company specializes in producing recombinant human coagulation factors, such as Factor VIIa and Factor VIII, which are used in the treatment of hemophilia and related bleeding disorders.

Average Trading Volume: 135,187,016

Technical Sentiment Signal: Buy

Current Market Cap: HK$94.07B

See more data about 1177 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1